Funding for this research was provided by:
Svenska Sällskapet för Medicinsk Forskning (P16-0026)
Received: 7 October 2021
Accepted: 27 June 2022
First Online: 23 August 2022
: J.D.B. reports non-financial support from Kite–Gilead during the conduct of the study, grants from Merck, Genentech, BMS, Kite–Gilead, Acerta, Seattle Genetics and Pharmacyclics and grants from Janssen outside the submitted work. No other disclosures were reported.
Free to read: This content has been made available to all.